Alana Harris Dent

Array ( [id] => 7807177 [patent_doc_number] => 20120058131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-08 [patent_title] => 'PTA089 PROTEIN' [patent_app_type] => utility [patent_app_number] => 13/145770 [patent_app_country] => US [patent_app_date] => 2010-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 41935 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0058/20120058131.pdf [firstpage_image] =>[orig_patent_app_number] => 13145770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6514815 [patent_doc_number] => 20100211066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-08-19 [patent_title] => 'Use of IMP3 as a Prognostic Marker for Cancer' [patent_app_type] => utility [patent_app_number] => 12/690647 [patent_app_country] => US [patent_app_date] => 2010-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 29252 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0211/20100211066.pdf [firstpage_image] =>[orig_patent_app_number] => 12690647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6175864 [patent_doc_number] => 20110177525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-21 [patent_title] => 'ANTIBODIES AND METHODS OF DIAGNOSING DISEASES' [patent_app_type] => utility [patent_app_number] => 12/689542 [patent_app_country] => US [patent_app_date] => 2010-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9824 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0177/20110177525.pdf [firstpage_image] =>[orig_patent_app_number] => 12689542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6514097 [patent_doc_number] => 20100216713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-08-26 [patent_title] => 'NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF PRLR' [patent_app_type] => utility [patent_app_number] => 12/686334 [patent_app_country] => US [patent_app_date] => 2010-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 25675 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0216/20100216713.pdf [firstpage_image] =>[orig_patent_app_number] => 12686334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7510054 [patent_doc_number] => 20110256167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-20 [patent_title] => 'IMMUNOSTIMULATING SAPONINS FOR USE IN SITU TUMOR-DESTRUCTION THERAPY' [patent_app_type] => utility [patent_app_number] => 13/141157 [patent_app_country] => US [patent_app_date] => 2009-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3383 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0256/20110256167.pdf [firstpage_image] =>[orig_patent_app_number] => 13141157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16499858 [patent_doc_number] => 10865233 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-15 [patent_title] => NKG2D-fc for immunotherapy [patent_app_type] => utility [patent_app_number] => 13/140469 [patent_app_country] => US [patent_app_date] => 2009-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 18099 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13140469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6550305 [patent_doc_number] => 20100233172 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-09-16 [patent_title] => 'METHODS OF INHIBITING QUIESCENT TUMOR PROLIFERATION' [patent_app_type] => utility [patent_app_number] => 12/639083 [patent_app_country] => US [patent_app_date] => 2009-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 154 [patent_figures_cnt] => 154 [patent_no_of_words] => 27074 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12639083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9581690 [patent_doc_number] => 08771691 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-07-08 [patent_title] => 'Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma' [patent_app_type] => utility [patent_app_number] => 13/139907 [patent_app_country] => US [patent_app_date] => 2009-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6063 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13139907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7662181 [patent_doc_number] => 20110311450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-22 [patent_title] => 'POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS' [patent_app_type] => utility [patent_app_number] => 13/131879 [patent_app_country] => US [patent_app_date] => 2009-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 77 [patent_figures_cnt] => 77 [patent_no_of_words] => 88241 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0311/20110311450.pdf [firstpage_image] =>[orig_patent_app_number] => 13131879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6476900 [patent_doc_number] => 20100285023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-11 [patent_title] => 'DETECTING CYP24 EXPRESSION LEVEL AS A MARKER FOR PREDISPOSITION TO CANCER' [patent_app_type] => utility [patent_app_number] => 12/633643 [patent_app_country] => US [patent_app_date] => 2009-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 22899 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0285/20100285023.pdf [firstpage_image] =>[orig_patent_app_number] => 12633643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6372520 [patent_doc_number] => 20100080769 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-01 [patent_title] => 'Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies' [patent_app_type] => utility [patent_app_number] => 12/629472 [patent_app_country] => US [patent_app_date] => 2009-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3713 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0080/20100080769.pdf [firstpage_image] =>[orig_patent_app_number] => 12629472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6616914 [patent_doc_number] => 20100099742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-22 [patent_title] => 'Sensitizing Cells for Apoptosis by Selectively Blocking Cytokines' [patent_app_type] => utility [patent_app_number] => 12/628055 [patent_app_country] => US [patent_app_date] => 2009-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 15665 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0099/20100099742.pdf [firstpage_image] =>[orig_patent_app_number] => 12628055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7669101 [patent_doc_number] => 20110318370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-29 [patent_title] => 'CXCL4L1 AS A BIOMARKER OF PANCREATIC CANCER' [patent_app_type] => utility [patent_app_number] => 13/131084 [patent_app_country] => US [patent_app_date] => 2009-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9584 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13131084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7579731 [patent_doc_number] => 20110293614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-01 [patent_title] => 'ISOFORM SPECIFIC ANTI-HER4 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/130789 [patent_app_country] => US [patent_app_date] => 2009-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 44280 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0293/20110293614.pdf [firstpage_image] =>[orig_patent_app_number] => 13130789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6495312 [patent_doc_number] => 20100286061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-11 [patent_title] => 'PLASMIN-INHIBITORY THERAPIES' [patent_app_type] => utility [patent_app_number] => 12/623954 [patent_app_country] => US [patent_app_date] => 2009-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 17763 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0286/20100286061.pdf [firstpage_image] =>[orig_patent_app_number] => 12623954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7566973 [patent_doc_number] => 20110287036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-24 [patent_title] => 'NOVEL CANCER TARGETING THERAPY USING COMPLEX OF SUBTANCE CAPABLE OF BINDING SPECIFICALLY TO CONSTITUENT FACTOR OF CANCER STROMA AND ANTI-TUMOR COMPOUND' [patent_app_type] => utility [patent_app_number] => 13/129710 [patent_app_country] => US [patent_app_date] => 2009-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 16200 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0287/20110287036.pdf [firstpage_image] =>[orig_patent_app_number] => 13129710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9607676 [patent_doc_number] => 08784840 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-07-22 [patent_title] => 'Method for screening modulators of apoptosis' [patent_app_type] => utility [patent_app_number] => 12/617653 [patent_app_country] => US [patent_app_date] => 2009-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 17130 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12617653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6550266 [patent_doc_number] => 20100233170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-09-16 [patent_title] => 'Fully human antibodies against N-Cadherin' [patent_app_type] => utility [patent_app_number] => 12/590601 [patent_app_country] => US [patent_app_date] => 2009-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 17275 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0233/20100233170.pdf [firstpage_image] =>[orig_patent_app_number] => 12590601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6024856 [patent_doc_number] => 20110053182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-03 [patent_title] => 'DIAGNOSIS OF PRE-CANCEROUS CONDITIONS USING PCDGF AGENTS' [patent_app_type] => utility [patent_app_number] => 12/613273 [patent_app_country] => US [patent_app_date] => 2009-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39868 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0053/20110053182.pdf [firstpage_image] =>[orig_patent_app_number] => 12613273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7686061 [patent_doc_number] => 20100120080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-05-13 [patent_title] => 'CANCER DIAGNOSIS USING KI-67' [patent_app_type] => utility [patent_app_number] => 12/610201 [patent_app_country] => US [patent_app_date] => 2009-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 10800 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0120/20100120080.pdf [firstpage_image] =>[orig_patent_app_number] => 12610201 [rel_patent_id] =>[rel_patent_doc_number] =>)